These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11295542)

  • 1. Small, but deadly: small-molecule inhibition of Bcl-2 homologue heterodimerization.
    Dewson G
    Trends Biochem Sci; 2001 Apr; 26(4):218-9. PubMed ID: 11295542
    [No Abstract]   [Full Text] [Related]  

  • 2. Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death.
    Shangary S; Johnson DE
    Biochemistry; 2002 Jul; 41(30):9485-95. PubMed ID: 12135371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex.
    Ernst JT; Becerril J; Park HS; Yin H; Hamilton AD
    Angew Chem Int Ed Engl; 2003 Feb; 42(5):535-9. PubMed ID: 12569483
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of dimerization of Bcl-2 family proteins by surface plasmon resonance.
    Xie Z; Reed JC
    Methods Enzymol; 2000; 322():266-74. PubMed ID: 10914024
    [No Abstract]   [Full Text] [Related]  

  • 5. Proteome-Wide Identification of On- and Off-Targets of Bcl-2 Inhibitors in Native Biological Systems by Using Affinity-Based Probes (AfBPs).
    Wang Z; Guo Z; Song T; Zhang X; He N; Liu P; Wang P; Zhang Z
    Chembiochem; 2018 Nov; 19(21):2312-2320. PubMed ID: 30133085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
    Konopleva M; Contractor R; Tsao T; Samudio I; Ruvolo PP; Kitada S; Deng X; Zhai D; Shi YX; Sneed T; Verhaegen M; Soengas M; Ruvolo VR; McQueen T; Schober WD; Watt JC; Jiffar T; Ling X; Marini FC; Harris D; Dietrich M; Estrov Z; McCubrey J; May WS; Reed JC; Andreeff M
    Cancer Cell; 2006 Nov; 10(5):375-88. PubMed ID: 17097560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms.
    Minn AJ; Kettlun CS; Liang H; Kelekar A; Vander Heiden MG; Chang BS; Fesik SW; Fill M; Thompson CB
    EMBO J; 1999 Feb; 18(3):632-43. PubMed ID: 9927423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions.
    Finnegan NM; Curtin JF; Prevost G; Morgan B; Cotter TG
    Br J Cancer; 2001 Jul; 85(1):115-21. PubMed ID: 11437412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Inhibition of BCL2 Shows Antitumor Effects in Lung Cancer.
    Cancer Discov; 2015 Jul; 5(7):OF21. PubMed ID: 26045015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 on the brink of breakthroughs in cancer treatment.
    Reed JC
    Cell Death Differ; 2018 Jan; 25(1):3-6. PubMed ID: 29227986
    [No Abstract]   [Full Text] [Related]  

  • 11. Structural conservation of residues in BH1 and BH2 domains of Bcl-2 family proteins.
    Gurudutta GU; Verma YK; Singh VK; Gupta P; Raj HG; Sharma RK; Chandra R
    FEBS Lett; 2005 Jul; 579(17):3503-7. PubMed ID: 15949801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activities of new di- and trimeric quinoline derivatives.
    Broch S; Hénon H; Debaud AL; Fogeron ML; Bonnefoy-Bérard N; Anizon F; Moreau P
    Bioorg Med Chem; 2010 Oct; 18(19):7132-43. PubMed ID: 20800501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biophysical characterization of the oligomeric state of Bax and its complex formation with Bcl-XL.
    Tan YJ; Beerheide W; Ting AE
    Biochem Biophys Res Commun; 1999 Feb; 255(2):334-9. PubMed ID: 10049709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BH4 domain of Bcl-2 as a novel target for cancer therapy.
    Liu Z; Wild C; Ding Y; Ye N; Chen H; Wold EA; Zhou J
    Drug Discov Today; 2016 Jun; 21(6):989-96. PubMed ID: 26631752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Mcl-1/Bcl-2 dual inhibitors created by the structure-based hybridization of drug-divided building blocks and a fragment deconstructed from a known two-face BH3 mimetic.
    Zhang Z; Su P; Li X; Song T; Chai G; Yu X; Zhang K
    Arch Pharm (Weinheim); 2015 Feb; 348(2):89-99. PubMed ID: 25641608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homology modeling and docking studies of human Bcl-2L10 protein.
    Bhargavi K; Kalyan Chaitanya P; Ramasree D; Vasavi M; Murthy DK; Uma V
    J Biomol Struct Dyn; 2010 Dec; 28(3):379-91. PubMed ID: 20919753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring pore formation by Bcl-2 family proteins.
    Schendel SL; Reed JC
    Methods Enzymol; 2000; 322():274-82. PubMed ID: 10914025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killing cancer cells by flipping the Bcl-2/Bax switch.
    Cory S; Adams JM
    Cancer Cell; 2005 Jul; 8(1):5-6. PubMed ID: 16023593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shooting at survivors: Bcl-2 family members as drug targets for cancer.
    Juin P; Geneste O; Raimbaud E; Hickman JA
    Biochim Biophys Acta; 2004 Mar; 1644(2-3):251-60. PubMed ID: 14996507
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiation-induced apoptosis in human myeloma cell line increases BCL-2/BAX dimer formation and does not result in BAX/BAX homodimerization.
    Filippovich IV; Sorokina NI; Lisbona A; Chérel M; Chatal JF
    Int J Cancer; 2001 Jun; 92(5):651-60. PubMed ID: 11340567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.